Keith Kaye
Adjunct Professor of Internal Medicine
Medical School
[email protected]
Available to mentor
Keith Kaye
Adjunct Professor
Manage Your Profile
Recent Publications
-
Gottesdiener LS, Li Y, Greenwood-Quaintance KE, Komarow L, Arias CA, Cober E, Herc ES, Kaye KS, Huskins WC, Figueroa J, Vilchez S, Fries BC, Leroi M, McCarty TP, Rioseco ML, Munita JM, Stryjewski ME, Reyes J, Chen L, Kreiswirth BN, Hill C, Baum K, Villegas MV, Paterson DL, Bonomo RA, Chambers HF, Fowler VG, Patel R, Doi Y, van Duin D, Satlin MJ, Antibacterial Resistance Leadership Group . Antimicrob Agents Chemother, 2026 May 15; e0038825Journal ArticleResistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study.
DOI:10.1128/aac.00388-25 PMID: 42138639 -
Albin O, Dickson RP, Rao K, Wunderink RG, Pogue J, Kaye KS. American Journal of Respiratory and Critical Care Medicine, 2026 May 20; 212 (Supplement_1): aamag162.4537Journal ArticleD17-07 Derivation and Preliminary Validation of Novel Hierarchical Composite Endpoints for Severe Pneumonia Clinical Trials
DOI:10.1093/ajrccm/aamag162.4537 -
Bjerklund JTE, Bahrs C, Batura D, Bruyere F, Cai T, Etienne M, Graugaard-Jensen C, Joseph A, Kaye KS, Koves B, Kranz J, Lanzafame M, Livermore DM, Medina-Polo J, de Novales FJM, Naber KG, Nickel JC, Oliva A, Schneidewind L, Soriano A, Tandogdu Z, Wagenlehner FME, Zahl PH. European Urology, 2026 Feb 15; 89: s1 - s2.Journal ArticleA0150 Heterogeneity causes unacceptable risks of bias in studies on new antibiotics and requires abandonment of the concept of complicated Urinary Tract Infection (cUTI)
DOI:10.1016/s0302-2838(26)00212-5 -
Dhar S, Valyko A, Kaye KS, Washer L. Infect Dis Clin North Am, 2026 Feb 26;Journal ArticleBlueprint for a Successful Infection Prevention Program.
DOI:10.1016/j.idc.2026.01.001 PMID: 41760409 -
Shorr A, Kaye KS, Zilberberg MD, Steenbergen JN, Chitra S, Bjork L, Rodriguez M. Open Forum Infectious Diseases, 2026 Jan 13; 13 (Supplement_1): ofaf695.1363Journal ArticleP-1170. Impact of Increased Severity of Illness on Outcomes in Complicated Urinary Tract Infections (cUTI) from ZEUS, a Randomized Controlled Trial (RCT) Evaluating IV Fosfomycin (IV-FOS)
DOI:10.1093/ofid/ofaf695.1363 PMID: PMC12791507 -
Pogue JM, Kaye KS, Chitra S, Wagenaar R, Rodriguez M, Steenbergen JN. Open Forum Infectious Diseases, 2026 Jan 13; 13 (Supplement_1): ofaf695.1364Journal ArticleP-1171. Assessment of the Fosfomycin 200 µg Disk Diffusion against Resistant Enterobacterales: Data from the Intravenous Fosfomycin (IV-FOS) Clinical Trial Program for Complicated Urinary Tract Infection
DOI:10.1093/ofid/ofaf695.1364 PMID: PMC12792206 -
Kaye KS, Rodriguez M, Chitra S, Steenbergen JN. Open Forum Infectious Diseases, 2026 Jan 13; 13 (Supplement_1): ofaf695.1365Journal ArticleP-1172. Characterization of Clinical Pathogens and Microbiological Outcomes for Patients Treated with IV Fosfomycin (IV-FOS) in the ZEUS Phase 2/3 Complicated Urinary Tract Infection, including Acute Pyelonephritis (cUTI/AP) Trial
DOI:10.1093/ofid/ofaf695.1365 PMID: PMC12791921 -
Ibrahim A, Kaye KS, Yalamanchili P, Zhao K, Mills JP, Pedrani M, Kirn T, Azim AA, kumar S, Narayanan N. Open Forum Infectious Diseases, 2026 Jan 13; 13 (Supplement_1): ofaf695.1818Journal ArticleP-1642. Epidemiology of Antimicrobial-Resistant Pathogens Across Eras of SARS-CoV-2 Variants in a Large New Jersey Hospital
DOI:10.1093/ofid/ofaf695.1818 PMID: PMC12793131
